PCM
MRSN

Pinz Capital Management’s Mersana Therapeutics MRSN Stock Holding History

Pinz Capital Management’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-16,000
Closed -$1.6M – 244
2022
Q1 		$1.6M Buy
+16,000
New +$1.87M 1% 37
2020
Q3 		– Sell
-2,420
Closed -$1.42M – 158
2020
Q2 		$1.42M Buy
+2,420
New +$826K 0.65% 75

Other funds holding MRSN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Pinz Capital Management's MRSN Position: Q2 2022 in Review

Pinz Capital Management sold out of Mersana Therapeutics (MRSN) in Q2 2022, closing a stake of 16,000 shares — an estimated $1.6M sold.

Pinz Capital Management first reported a position in MRSN in Q2 2020 and held it in 2 quarters. The position peaked at $1.6M in Q1 2022. 126 funds tracked by Wall St. Rank hold MRSN as of Q2 2022.

  • Pinz Capital Management reported no remaining Mersana Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Pinz Capital Management sold 16,000 Mersana Therapeutics shares in Q2 2022, an estimated $1.6M.
  • Pinz Capital Management first reported a position in Mersana Therapeutics in Q2 2020 and held it in 2 quarters.
  • Pinz Capital Management's Mersana Therapeutics position peaked at $1.6M in Q1 2022.
  • 126 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q2 2022.

Based on Pinz Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.